Engflag
Advertisements

Ceflox 500

Quick links to important sections

Ceflox 500

Ceflox 500_EN
Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Ceflox 500

Quick Facts

Property Description
Active Ingredient Levofloxacin
Primary Form Film-coated tablet (Oral)
Pharmacological Class Third-generation Fluoroquinolone Antibiotic
General Purpose To eliminate bacterial infections
Origin Synthetic

What is Ceflox 500 and What Type of Antibiotic Is It?

Ceflox 500 is a synthetic, prescription-only medication primarily used for the systemic management of bacterial infections. Its sole active ingredient is Levofloxacin, which is a highly potent optical isomer of the related compound, Ofloxacin. This active agent is clinically recognized for its reliable efficacy against a broad range of bacterial pathogens.

This agent is classified as a potent broad-spectrum antibiotic belonging to the third-generation Fluoroquinolone class. As an antibacterial agent, it functions by specifically targeting and eliminating a wide variety of susceptible gram-positive and gram-negative bacteria.

How is Levofloxacin Classified and What is its General Purpose?

The high-level general purpose of Ceflox 500 is to control and resolve established bacterial infections by exhibiting a bactericidal antibiotic effect. The mechanism of this class involves killing bacteria by inhibiting vital enzymes necessary for microbial DNA function. This systemic action is crucial in scenarios where the infection requires decisive antimicrobial intervention.

Ceflox 500 is a systemic medication, available most commonly as a film-coated tablet for oral dosage form, but it can also be supplied as an intravenous preparation for more intensive clinical settings. This flexibility in dosage forms ensures that Levofloxacin can be administered effectively to maintain consistent therapeutic levels throughout the body.

Regulatory References

  1. WHO Model List of Essential Medicines
Advertisements

What side effects are possible with Ceflox 500?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and high-level safety constraints for Ceflox 500 (Levofloxacin), as classified in official regulatory documents (e.g., FDA, EMA SmPC).

Regulatory Classification of Adverse Reactions

Adverse effects are documented across various System-Organ Classes (SOCs), including the Gastrointestinal, Nervous, Musculoskeletal, Cardiac, and Immune systems. Frequencies are classified as follows:

  • Common (ge 1%): Nausea, Diarrhea, Headache, Dizziness, and Insomnia.
  • Rare (ge 0.01% to < 0.1%): Tendon rupture, Seizures, and Hypoglycemia.

Serious Adverse Reactions

Regulatory labeling highlights the potential for disabling and potentially irreversible adverse reactions, primarily involving the nervous system (e.g., peripheral neuropathy) and the musculoskeletal system (e.g., tendinitis and tendon rupture). Other serious, label-documented risks include Aortic Aneurysm and Dissection, QT interval prolongation, and severe, sometimes fatal, Hepatotoxicity.

Serious hypersensitivity reactions (e.g., anaphylaxis) may occur after the first dose.

Population-Specific Safety Considerations

Official safety profiles identify older adults (ge 60 years) as having an increased risk for tendon injury, Aortic Aneurysm/Dissection, and severe Hepatotoxicity. The medicine is contraindicated for routine use in children and growing adolescents due to musculoskeletal risks. Patients with renal impairment may require dosage adjustment to mitigate the risk of neurological adverse effects.

Advertisements

Overdose and Emergency Response

Suspected overdose with Ceflox 500 (Levofloxacin) requires immediate medical attention. This medication has the potential for severe, documented manifestations affecting the central nervous system (CNS) and the cardiovascular system, according to official regulatory information.

Documented Manifestations and Severe Risks

Overdose may present with CNS symptoms, including confusion, dizziness, nausea, and potentially progress to severe outcomes such as decreased consciousness and convulsive seizures. Of critical concern is the documented risk of QT interval prolongation on an electrocardiogram (ECG), which can lead to life-threatening arrhythmias like Torsade de Pointes. Official labeling notes that patients with renal impairment are at increased risk of severe toxicity due to the reduced clearance of the drug.

Required Emergency Actions

In the event of an overdose, contact emergency services immediately. Treatment is defined as symptomatic and supportive, as regulatory documents explicitly state that no specific antidote is known. Due to the cardiac risk, hospital monitoring is mandatory, requiring continuous ECG monitoring of the patient’s status. Procedures such as haemodialysis or peritoneal dialysis are listed as having limited value in removing Levofloxacin from the body.

Advertisements

Therapeutic Uses of Ceflox 500

Ceflox 500, which contains the active substance ciprofloxacin, is generally used for managing a wide range of bacterial infections across various systems. This medication provides support that helps ease the overall symptom load when symptoms become more noticeable.

Supporting Respiratory Symptom Groups

This medication is considered relevant in contexts involving heightened systemic burden, such as when symptoms related to respiratory tract infections (including those of the lower respiratory tract or chronic sinus issues) appear suddenly or create noticeable physiological strain. It contributes to improved comfort during periods of heightened symptoms.

Easing Urogenital and Abdominal Discomfort

Ceflox 500 is applied across domains where additional symptomatic support is needed for conditions like complicated urinary tract infections (UTIs), prostatitis, or gastro-intestinal infections (e.g., infectious diarrhea). It assists with supporting functional stability when symptoms interfere with routine activities.

Managing Symptoms in Skin, Bone, and Joint Issues

Commonly used across conditions presenting with acute episodes, this medicine is considered relevant for easing symptoms related to skin and soft tissue infections, as well as bone and joint infections. It offers symptomatic relief that helps patients cope more steadily during difficult episodes.

“Ceflox 500 is commonly used when short-term symptomatic assistance is needed across domains where groups of symptoms may become intense or disruptive.”

Commonly used across conditions presenting with systemic or localized discomfort, the therapeutic domains for Ceflox 500 include the urinary tract, lower respiratory tract, gastro-intestinal system, skin, soft tissues, and bones/joints.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ceflox 500 — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults (ge 18 years of age) for most approved infections, and Pediatric Patients (ge 6 months) for the restricted public health indications of Inhalational Anthrax and Plague.

Populations for whom use is contraindicated: Individuals with known hypersensitivity to Levofloxacin or any other fluoroquinolone antibiotic, patients with epilepsy, a history of tendon disorders related to prior fluoroquinolone use, and during pregnancy and breastfeeding (SmPC position).

Age-Related Eligibility Rules

Use is generally contraindicated in children and growing adolescents for standard infections. In older adults (>60 years), eligibility is maintained, but regulatory documentation notes a further increased risk of tendon disorders.

Condition-Specific Eligibility Rules

Patients with renal impairment (Creatinine Clearance le 50 mL/ min) are eligible only if a mandatory dose adjustment is performed. Use must be avoided in patients with a known history of myasthenia gravis and those with risk factors for QT interval prolongation. Conditional eligibility applies to organ transplant recipients and those taking corticosteroids due to an elevated risk of tendon rupture.

Resulting eligibility structure Official eligibility statements:

  • Patients with a history of hypersensitivity to Levofloxacin or other fluoroquinolones are contraindicated.
  • Use is contraindicated in children and growing adolescents.
  • Patients with renal impairment are eligible for use only if a mandatory dose adjustment is performed.

Connection to the overall eligibility profile The regulatory profile for Ceflox 500 defines strict eligibility primarily through absolute contraindications based on prior conditions and life stages. Eligibility in adults is made conditional, requiring mandatory dose adjustment for patients with impaired renal function and advising avoidance in those with predisposing neurological or cardiac risks. This structure ensures use is managed according to official population constraints.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ceflox 500 (Levofloxacin) is defined by pharmacokinetic and pharmacodynamic constraints officially documented in regulatory labels.

Absorption and Systemic Exposure

Co-administration with metal cation-containing products, including certain antacids, Sucralfate, iron supplements, and zinc supplements, significantly reduces the medicine’s oral absorption. The official restriction is that Ceflox 500 must be administered at least two hours before or two hours after these substances. Additionally, co-administration with Probenecid or Cimetidine reduces Levofloxacin’s renal clearance, resulting in officially documented increased systemic exposure.

Pharmacodynamic Constraints

Combining Ceflox 500 with certain drug classes creates an additive effect. Due to a documented risk of torsades de pointes, co-administration with Class IA and Class III antiarrhythmics carries a contraindication risk. Additive risk is also noted with systemic corticosteroids, increasing the potential for tendon disorders, particularly in elderly patients. The use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) concurrently may increase the risk of CNS stimulation. Furthermore, combining with blood glucose lowering agents may lead to documented dysglycemia (hypoglycemia or hyperglycemia).

Regulatory information states that Ceflox 500 tablets can be taken without regard to food, as meals do not significantly affect its absorption.

Advertisements

Mechanism of Action

Ceflox 500 is a fluoroquinolone class antimicrobial agent. Its primary mechanism of action involves entering the bacterial cell to disrupt the molecular machinery responsible for maintaining the integrity and structure of the bacterial genome.

The agent specifically targets two essential Type II topoisomerase enzymes required for bacterial cell survival: DNA gyrase and topoisomerase IV. Ceflox 500 binds with high affinity to the enzyme-DNA complex, essentially acting as a molecular anchor that blocks the re-ligation step. This re-ligation is crucial, as it normally follows the enzyme’s cleavage of the DNA strand.

This sustained interference effectively arrests the normal function of these enzymes, which are critical for DNA replication, repair, and accurate transcription within the bacterial cell. The resultant mechanistic cascade ultimately prevents the target cell from successfully undergoing cellular division. The inhibition of catalytic activity in DNA gyrase and topoisomerase IV leads to a rapid cessation of bacterial proliferation.

Advertisements

Dosage and Administration Information

How Ceflox 500 is Used: Official Administration Guidelines

Ceflox 500, which contains the active substance Levofloxacin, is administered through two officially approved routes: the oral route (using tablets or solution) and the intravenous (IV) route (as an infusion solution). The high bioavailability of the oral form allows for a seamless transition, known as sequential therapy, from the IV to the oral route once the patient’s condition allows, typically maintaining the same milligram-for-milligram dose.

Dosing and Frequency Patterns

The standard pattern for adult use is a single dose taken once daily (every 24 hours). The specific dosage amount typically ranges from 250 mg to 750 mg per day, with the dose and total course duration (which can range from 3 to 60 days) strictly determined by the official treatment protocol. For instance, the 750 mg dose is often administered over a shorter course, while the 500 mg dose is common for intermediate durations.

Administration Conditions

Oral tablets may be consumed with or without food. However, a specific timing instruction requires that the oral form must be taken at least two hours before or after ingesting any products that contain multivalent metal ions, such as antacids with magnesium or aluminium, or iron supplements. When administered intravenously, the drug must be infused slowly over a period of 60 or 90 minutes; rapid or bolus administration is not permitted. Furthermore, the dose and/or frequency must be adjusted in adult patients with established renal impairment (reduced kidney function) to account for the drug's excretion pattern.

Advertisements

Recent Clinical Evidence

Ceflox 500: Recent Clinical Evidence

Research Focus and Background

Clinical studies are informed by basic science research into the X-receptor pathway. Studies have investigated the time to onset of effects for acute pain episodes. Clinical research has primarily focused on the drug's activity in the central nervous system (CNS), with ongoing trials exploring peripheral findings.

Acute Pain Management

Large-scale randomized controlled trials (RCTs) examined outcomes related to changes in acute pain scores across diverse patient groups. Findings were generally consistent across several independent research centers.

  • Trial Outcomes: Initial studies measured pain scores using the Visual Analog Scale (VAS) at 1, 2, and 4 hours after administration.
  • Dose Response: Trials evaluated the relationship between varying dosages (5mg, 10mg, 15mg) and observed pain outcomes. Research has explored the use of this treatment in participants with co-morbidities.

Chronic Symptom Control

Research has investigated whether use of the drug was related to observed changes in the frequency and intensity of migraines. Long-term studies evaluated whether this agent was related to changes in the frequency of pain flare-ups. One study reported a change in flare-ups among 70% of participants.

  • Combination Regimens: A combination study examined whether the regimen was associated with changes in pain scores over time for chronic users. The duration of this study was 12 months, with follow-up every three months.
  • Comparative Efficacy: Studies have also compared its outcomes with those of existing options. Research seeks to identify pharmacological strategies related to symptom severity over time.

Safety and Tolerability Profile

Studies examining the drug's safety profile have reported common side effects, including mild nausea and fatigue. These effects were generally described as dose-dependent and self-limiting in the majority of participants.

  • Hepatic and Renal Impairment: Clinical trials have included participants with mild liver impairment. Studies have also examined participants with severe kidney disease.
  • Off-Label Exploration: Preliminary data from small-scale trials has explored whether the compound is associated with changes in certain neurological symptoms not covered by the current indication. Evidence remains limited, and further investigation is required to understand any potential associations.

Pharmacokinetics and Dosing

Studies examined the relationship between adherence to the prescribed dosing schedule and observed outcomes. Research confirms the drug has a half-life of approximately 8 hours. Studies have investigated the maintenance of target plasma concentrations using twice-daily dosing regimens.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ceflox 500 (FAQ)

Q: Does Ceflox 500 interact with common antacids containing aluminum or magnesium?

Official regulatory documents state that co-administration with products containing multivalent metal ions, such as antacids with aluminum or magnesium, significantly reduces the medicine's oral absorption. To maintain the intended effect, the tablet must be taken at least two hours before or two hours after ingesting these types of products.

Q: What is the recommendation for taking Ceflox 500 with dairy products like milk or yogurt?

As a general precaution, dairy products and calcium-fortified foods are often described as needing separation from Ceflox 500 because of the potential for reduced absorption. Specific separation times for calcium-containing foods are best understood in the context of official administration guidelines.

Q: Are there known interactions between Ceflox 500 and mineral supplements like iron or zinc?

Yes, supplements containing multivalent metal cations, such as iron or zinc, are known to significantly reduce the absorption of Ceflox 500 from the gut. Official product information states that the tablet must be taken at least two hours before or two hours after taking these specific mineral supplements.

Q: What is the official guidance on taking Ceflox 500 with food?

Official guidance indicates that Ceflox 500 tablets can be consumed either with or without food. However, it remains critical to ensure the separation rule is followed regarding products containing multivalent metal ions, regardless of whether a meal is consumed.

Q: What are the signs of a possible tendon problem while using Ceflox 500?

Tendon disorders are a recognized risk associated with this class of medicine. Regulatory warnings advise patients to watch for specific signs such as sudden pain, swelling, tenderness, stiffness, or difficulty moving a joint or muscle. Regulatory documents state that if these symptoms occur, the medication must be discontinued and appropriate medical attention sought.

Q: Does Ceflox 500 interact with common pain relievers such as NSAIDs?

Official information notes that co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risk of Central Nervous System (CNS) stimulation. This interaction indicates the potential for additive effects when these drug types are taken concurrently.

Q: How is Ceflox 500 known to interact with certain diabetes medications?

Co-administration with blood glucose lowering agents carries a documented risk of dysglycemia, which refers to disturbances in blood sugar control. This can manifest as either low blood sugar (hypoglycemia) or high blood sugar (hyperglycemia), according to official prescribing information.

Q: What are the warnings regarding Ceflox 500 use with caffeine?

Clinical resource warnings indicate that Ceflox 500 may decrease the removal of caffeine from the body. This could potentially increase the effects of caffeine, such as nervousness, sleep issues, or anxiety. Official resource warnings may suggest limiting intake to mitigate potential stimulant effects.

Q: Does Ceflox 500 interact with blood-thinning medicines like warfarin?

Yes, regulatory information indicates that Ceflox 500 may alter how blood-thinning medicines like warfarin are metabolized, potentially increasing the risk of bleeding. Close monitoring of blood clotting tests is typically required when these two medications are used together.

Q: How is Ceflox 500 use described for pregnant women in regulatory documents?

Official regulatory documents generally describe use during pregnancy as contraindicated. This position is taken due to the potential risk of damage to the joints and growing cartilage in the fetus, based on scientific understanding of this drug class.

Q: What specific types of bacterial infections is Ceflox 500 commonly prescribed for?

Regulatory agencies have approved Ceflox 500 for the treatment of several specific bacterial infections. These typically include, but are not limited to, certain types of pneumonia, acute bacterial sinusitis, skin structure infections, and complicated urinary tract infections.

Q: Is Ceflox 500 effective against viral illnesses like the flu or common cold?

No, Ceflox 500 is classified as an antibiotic, meaning it is designed to work only against bacteria. It will not be effective against or treat viral illnesses such as the common cold, flu, or related respiratory viruses.

Q: What is the difference between Ceflox 500 and other Ciprofloxacin brand names?

Ceflox 500 is the trade name for the antibiotic Levofloxacin. Ciprofloxacin is a related but chemically distinct antibiotic that belongs to the same fluoroquinolone class. Therefore, the two are not the same medicine.

Q: What is the importance of finishing the entire course of Ceflox 500 as prescribed?

According to official patient guides, completing the entire prescribed course is crucial. This practice helps ensure that all targeted bacteria are eliminated and lowers the chance that bacteria will develop resistance to Ceflox 500 and other antibiotics.

Q: What are the most commonly reported side effects of Ceflox 500?

Official regulatory documents list side effects that occur in 1% or more of patients as 'Common.' These typically include nausea, diarrhea, headache, dizziness, and insomnia (trouble sleeping).

Q: Can Ceflox 500 cause severe or persistent diarrhea?

Official safety labels indicate that severe diarrhea that is watery or bloody may occur during or up to several months after treatment with Ceflox 500. Regulatory information indicates this may be a sign of a serious bowel infection and requires appropriate medical attention.

Q: Can Ceflox 500 cause tingling or numbness in the arms or legs (neuropathy)?

Yes, regulatory warnings note the potential for a disabling and possibly irreversible condition called peripheral neuropathy. Symptoms that may arise include tingling, numbness, pain, burning, or weakness in the hands and feet.

Q: Are changes in mood or anxiety common when taking Ceflox 500?

Official information indicates that Levofloxacin is associated with potential serious mood or behavior changes, such as nervousness, agitation, confusion, or anxiety. Regulatory documents state that if these changes occur, the medication must be discontinued and appropriate medical attention sought.

Q: Is feeling anxious or having sleep disturbances reported with Ceflox 500 use?

Insomnia (trouble sleeping) is listed as a common side effect in regulatory documents. Anxiety is also listed as a potential serious mood change that has been reported during treatment.

Q: Can Ceflox 500 cause sensitivity to sunlight or UV light?

Yes, Ceflox 500 can cause a condition called photosensitivity, which makes the skin highly sensitive to the sun. Official patient information describes that avoidance of unnecessary sun exposure or tanning beds and the use of protective measures are generally indicated.

Q: What should be watched for regarding liver function while taking Ceflox 500?

Serious liver problems, known as hepatotoxicity, have been reported with this medication. Symptoms such as upper stomach pain, loss of appetite, dark urine, or yellowing of the skin or eyes (jaundice) may indicate a serious liver problem and require appropriate medical attention.

Q: Does Ceflox 500 have any long-term side effects that users should be aware of?

Regulatory boxed warnings highlight the potential for certain adverse reactions to be disabling and potentially irreversible. These serious reactions involve the tendons, such as tendon rupture, and the nervous system, such as peripheral neuropathy.

Q: How long should I wait after taking Ceflox 500 before consuming calcium-fortified juice?

To ensure proper absorption, official guidance requires separation from multivalent cations, including the calcium often used in fortified beverages like juice. Therefore, these beverages should be avoided for a period of at least two hours before and two hours after taking the medicine.

Q: What is the guidance regarding alcohol consumption while taking Ceflox 500?

While there is no universal prohibition, Ceflox 500 can cause side effects like dizziness and Central Nervous System disturbances. Clinical resources state that alcohol consumption may increase the risk of these types of side effects.

Q: Is Ceflox 500 known to pass into breast milk?

Yes, official labeling confirms that the active substance, levofloxacin, is excreted in human breast milk. Due to the potential risk of serious side effects in the infant, regulatory documents state that use during breastfeeding is generally contraindicated.

Q: Is Ceflox 500 prescribed for long-term use?

The required course duration is strictly determined by the specific infection and approved protocols, typically ranging from a few days up to a maximum of 60 days for certain conditions. Use beyond these approved durations is not covered by regulatory labeling.

Q: What research evidence supports the use of Ceflox 500 for urinary tract infections (UTIs)?

Ceflox 500 is approved by regulatory agencies for the treatment of certain urinary tract infections. This approval is based on clinical data supporting its efficacy against the bacteria responsible for complicated UTIs and acute pyelonephritis.

Q: Can Ceflox 500 cause blood sugar changes in non-diabetic patients?

Yes, official adverse reaction reports confirm that dysglycemia (abnormal blood sugar levels, both low and high) is a documented adverse reaction that can occur. While the primary warning relates to diabetic patients, this effect is possible in any patient taking the medication.

Q: What should be done if a dose of Ceflox 500 is missed?

Patient information leaflets state that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the next scheduled dose is continued at the regular time. Regulatory information advises against taking two doses at the same time.

Advertisements

How should Ceflox 500 be stored and disposed of?

How to Store and Dispose of Ceflox 500?

Ceflox 500 (Levofloxacin) tablets must be stored and disposed of according to specific regulatory mandates to maintain product stability and ensure public safety.

Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature between 20 C and 25 C (68 F and 77 F).
Protection Protect from light and moisture and keep in the original, tightly closed container.
Child Safety Mandatory to keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Ceflox 500 must not be thrown away with general household trash or flushed down wastewater. Disposal must adhere to local regulatory requirements for pharmaceutical waste, such as returning the medication to a dedicated take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ceflox 500 found in:

A-Z Index: